Pages that link to "Q40404804"
Jump to navigation
Jump to search
The following pages link to A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells (Q40404804):
Displaying 50 items.
- Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches (Q21129299) (← links)
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy (Q26773309) (← links)
- Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors (Q26795540) (← links)
- CAR T Cell Therapy: A Game Changer in Cancer Treatment (Q26822769) (← links)
- CARs in chronic lymphocytic leukemia -- ready to drive (Q26830526) (← links)
- From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies (Q26852919) (← links)
- Adoptive T-cell therapy for Leukemia (Q27006934) (← links)
- Cellular immunotherapy for pediatric solid tumors (Q27014912) (← links)
- Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies (Q27027243) (← links)
- Are BiTEs the "missing link" in cancer therapy? (Q28083907) (← links)
- An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers (Q28551080) (← links)
- Sleeping beauty system to redirect T-cell specificity for human applications (Q30535187) (← links)
- Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice (Q33560416) (← links)
- Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts (Q33606096) (← links)
- Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. (Q33713042) (← links)
- Immunotherapy in acute leukemia (Q33731552) (← links)
- 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies (Q33819935) (← links)
- 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells (Q33884816) (← links)
- The basic principles of chimeric antigen receptor design (Q34036213) (← links)
- CAR-modified T-cell therapy for cancer: an updated review. (Q34044213) (← links)
- Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. (Q34055865) (← links)
- In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) (Q34073529) (← links)
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor (Q34122292) (← links)
- Immunotherapy of human cancers using gene modified T lymphocytes (Q34188383) (← links)
- Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors (Q34205181) (← links)
- Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects (Q34235597) (← links)
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions (Q34248531) (← links)
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects (Q34256494) (← links)
- Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. (Q34270375) (← links)
- Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy (Q34431441) (← links)
- Genetically engineered T cells for the treatment of cancer (Q34645898) (← links)
- Antibody-based immunotherapy in high-risk neuroblastoma (Q34725758) (← links)
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients (Q34876434) (← links)
- The promise and potential pitfalls of chimeric antigen receptors (Q34970378) (← links)
- Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. (Q34987908) (← links)
- Immunotherapy for malignant glioma (Q35114086) (← links)
- Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells (Q35328354) (← links)
- T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo (Q35483599) (← links)
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. (Q35587352) (← links)
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma (Q35604043) (← links)
- PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor (Q35623431) (← links)
- Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells (Q35651760) (← links)
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors (Q35690389) (← links)
- K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo (Q35812085) (← links)
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. (Q35834087) (← links)
- T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells (Q35848840) (← links)
- Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors (Q35877585) (← links)
- Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade (Q35922726) (← links)
- Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease (Q36007685) (← links)
- Genetically modified T-cell therapy for osteosarcoma (Q36198232) (← links)